→ Soon-to-be-ex-Genzyme head David Meeker has added another biotech board position to his resume. Just a few days after being named chairman at Rhythm, South San Francisco-based MyoKardia has named Meeker to the board. Meeker will be leaving Genzyme after a long career in June.
→ J&J’s DePuy Synthes Products has acquired 3D printing technology from Tissue Regeneration Systems. DePuy plans to use the technology to “create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopedic and craniomaxillofacial deformities and injuries.” Financial terms of the transaction have not been disclosed.
→ Atara Biotherapeutics, which is working on allogeneic T cell therapies, signed a 15-year lease of an approximately 90,000-square-foot building, the second largest in SRG’s 507,878-square-foot project in Thousand Oaks, Ca.
→ Cambridge, MA-based H3 Biomedicine is extending its collaboration with Foundation Medicine in search of new cancer drivers.
→ The European Commission has a one-word response to the UK’s insistence that it can still keep the EMA in London after the country exits the EU: Forgetaboutit. “The United Kingdom is leaving the European Union and it will have no say in the location of EU agencies,”said an EC spokesperson.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription